- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | BioCryst ends internal discovery programs, closes Alabama facility in pivot to cost-saving partnerships | ||
| Mo | Evommune's phase 2b trial flops, ending challenge to Novartis in hives | ||
| Mo | UK-based Scancell bids to buy Nasdaq-listed Neuphoria to 'increase profile' with US investors | ||
| Mo | Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis | ||
| Mo | AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor | ||
| Fr | Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says | ||
| Fr | Biogen ends Apellis research programs, cuts 'small number' of roles after $5.6B buyout | ||
| Fr | Moderna enters in vivo CAR-T, granting autoimmune asset '007' license to kill pathogenic cells | ||
| Do | Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision | ||
| Do | Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect | ||
| Mi | Spurned by FDA, Passage Bio finds exit through merger with Remix Therapeutics | ||
| Mi | Novartis pays Antares $105M to illuminate undruggable cancer targets | ||
| Mi | RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic | ||
| Mi | BIO 2026: Flagship inks research collaboration with Saudi sovereign wealth fund company | ||
| Mi | Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact | ||
| 23.06. | Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push | ||
| 23.06. | Serapha Bio takes flight from Boundless Bio merger with $230M and gene-editing prospect from China | ||
| 23.06. | Sangamo to put 'substantially all' assets for sale in bankruptcy, lines up Lilly and Astellas as buyers | ||
| 23.06. | Merck KGaA pledges $50M to build new cardio biotech with eye to later acquisition | ||
| 22.06. | Exelixis' Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review | ||
| 22.06. | Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months | ||
| 22.06. | In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy | ||
| 22.06. | Merck's anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis | ||
| 22.06. | AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect | ||
| 22.06. | Sanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.